Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials

Type 2 diabetes (T2D) is a complex, heterogeneous disease affecting a high proportion of people with a spectrum of comorbidities that may influence the optimal treatment pathway for each individual [1 –3]. Cardiovascular and renal comorbidities, alongside other factors such as disease duration and patient preference, affect both the setting of glycaemic targets and choice of specific glucose-lowering medications, as advised by current American Diabetes Association (ADA) clinical guidelines [4]. Achieving sustained glycaemic control can be challenging and often requires multiple concomitant medications for its maintenance.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research